Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 2,352 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Intravenous Clear all
Terminated Phase 1Phase 2 Interventional Results available

Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Artery

NCT01755858
View directory record Official record
Conditions
Renal Artery Obstruction, Hypertension, Renovascular, Ischemia Reperfusion Injury
Interventions
Bendavia, Placebo
Drug
Lead sponsor
Stealth BioTherapeutics Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 11, 2020 · Synced Oct 31, 2026, 5:05 PM EDT
Completed Phase 1Phase 2 Interventional

IVIG - West Nile Encephalitis: Safety and Efficacy

NCT00068055
View directory record Official record
Conditions
West Nile Virus
Interventions
Omr-lgG-am, Polygam® S/D, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
66
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2011 · Synced Oct 31, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

Study to Investigate Etokimab (ANB020) Activity in Adult Participants With Peanut Allergy

NCT02920021
View directory record Official record
Conditions
Peanut Allergy
Interventions
Etokimab, Placebo
Drug
Lead sponsor
AnaptysBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Palo Alto, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 31, 2026, 5:05 PM EDT
Completed Phase 2 Interventional

Study Evaluating the Safety and Efficacy of MN-221 as an Adjunct to Standard Therapy in Subjects Experiencing an Acute Exacerbation of Asthma

NCT00838591
View directory record Official record
Conditions
Asthma
Interventions
MN-221, Placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 65 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
15
States / cities
Loma Linda, California • San Diego, California • Sylmar, California + 11 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2013 · Synced Oct 31, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

A Study of LY3451838 in Participants With Migraine

NCT04498910
View directory record Official record
Conditions
Migraine
Interventions
LY3451838, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
9
States / cities
Phoenix, Arizona • Stamford, Connecticut • Ocala, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 31, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study Of PF-04427429 In Healthy Women Volunteers

NCT01511497
View directory record Official record
Conditions
Pain, Migraine Disorders
Interventions
PF-04427429, Normal saline
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years · Female only
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
3
States / cities
Miami, Florida • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Oct 31, 2026, 5:05 PM EDT
Withdrawn Phase 2 Interventional

Efficacy and Safety Study of Intravenous Belimumab Versus Placebo in Subjects With Idiopathic Membranous Nephropathy

NCT01762852
View directory record Official record
Conditions
Glomerulonephritis, Membranous
Interventions
Belimumab 10 mg, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
St Louis, Missouri • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Oct 31, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Clinical Study to Evaluate the Safety of CS-1103 in Healthy Participants

NCT06316973
View directory record Official record
Conditions
Substance Use Disorders, Methamphetamine Abuse, Methamphetamine Intoxication
Interventions
CS-1103, Sterile Saline
Drug
Lead sponsor
Clear Scientific, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 31, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of Tocilizumab on Patients With COVID-19

NCT04356937
View directory record Official record
Conditions
SARS-CoV 2
Interventions
Tocilizumab, Placebos
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
243 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
3
States / cities
Boston, Massachusetts • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 27, 2021 · Synced Oct 31, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability and Abuse Liability Study of Intravenous NRP104 in Adults With Stimulant Abuse Histories

NCT00247572
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity, Amphetamine-Related Disorders, Substance-Related Disorders
Interventions
NRP104
Drug
Lead sponsor
New River Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 5, 2007 · Synced Oct 31, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

Tocilizumab in Cardiac Transplantation

NCT03644667
View directory record Official record
Conditions
Heart Transplant
Interventions
tocilizumab, Placebo, Standard of Care Triple IS
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
20
States / cities
Beverly Hills, California • La Jolla, California • Stanford, California + 15 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2026 · Synced Oct 31, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus

NCT01406418
View directory record Official record
Conditions
Influenza
Interventions
CR6261 2 mg/kg, CR6261 5 mg/kg, CR6261 15 mg/kg, CR6261 30 mg/kg, CR6261 50 mg/kg, Placebo
Biological
Lead sponsor
Crucell Holland BV
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 19, 2013 · Synced Oct 31, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Serum Concentrations of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered in Multiple Doses and Routes to Healthy, HIV-uninfected Adults

NCT03387150
View directory record Official record
Conditions
HIV Infections
Interventions
VRC07-523LS, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
6
States / cities
Birmingham, Alabama • Atlanta, Georgia • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Oct 31, 2026, 5:05 PM EDT
Terminated Phase 2 Interventional Results available

Randomized, Placebo-controlled Trial of Ferric Carboxymaltose in RLS Patients With Iron-deficiency Anemia

NCT02826681
View directory record Official record
Conditions
Restless Legs Syndrome (RLS)
Interventions
Injectafer® (Ferric Carboxymaltose - FCM), Placebo (Normal Saline)
Drug
Lead sponsor
American Regent, Inc.
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
8
States / cities
Lemon Grove, California • Fort Myers, Florida • Orlando, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2025 · Synced Oct 31, 2026, 5:05 PM EDT
Recruiting Phase 2Phase 3 Interventional

Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT05327114
View directory record Official record
Conditions
Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Interventions
Nipocalimab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
16
States / cities
Centennial, Colorado • Coral Springs, Florida • Maitland, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 5:05 PM EDT
Completed Phase 2 Interventional

Repinotan in Patients With Acute Ischemic Stroke

NCT00044915
View directory record Official record
Conditions
Stroke, Acute Ischemic Stroke
Interventions
Repinotan HCl (BAYX3702), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
782 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
28
States / cities
Los Angeles, California • Oceanside, California • San Diego, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2009 · Synced Oct 31, 2026, 5:05 PM EDT
Completed Phase 2 Interventional

A Study of MCMV5322A/MCMV3068A for the Prevention of Cytomegalovirus Disease in High-Risk Kidney Allograft Recipients

NCT01753167
View directory record Official record
Conditions
Cytomegalovirus Infections
Interventions
MCMV3068A, MCMV5322A, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
15
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 31, 2026, 5:05 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Discovery and Analytical Validation of Inflammatory Bio-signatures of the Human Pain Experience

NCT05074485
View directory record Official record
Conditions
Pain
Interventions
anakinra, Placebo, Nociceptive pain challenge
Drug · Other
Lead sponsor
Alan Prossin
Other
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 31, 2026, 5:05 PM EDT
Terminated Phase 1 Interventional

Study to Assess the Safety and Tolerability of MEDI5117 in Rheumatoid Arthritis Patients

NCT01559103
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
MEDI5117, MEDI5117 Placebo
Biological
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
20 Years to 75 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 9, 2021 · Synced Oct 31, 2026, 5:05 PM EDT
Completed Phase 2 Interventional

CCI-779 in Treating Patients With Prostate Cancer

NCT00012142
View directory record Official record
Conditions
Prostate Cancer
Interventions
temsirolimus
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2004
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2013 · Synced Oct 31, 2026, 5:05 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Intravenous Neridronic Acid in Complex Regional Pain Syndrome (CRPS)

NCT03560986
View directory record Official record
Conditions
Complex Regional Pain Syndrome (CRPS)
Interventions
Neridronic acid 100 mg, Placebo
Drug
Lead sponsor
Grünenthal GmbH
Industry
Eligibility
18 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
41
States / cities
Cottonwood, Arizona • Tempe, Arizona • Tucson, Arizona + 34 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Oct 31, 2026, 5:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers

NCT03565861
View directory record Official record
Conditions
Safety Issues
Interventions
Placebo, NP10679
Drug
Lead sponsor
Neurop Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 13, 2019 · Synced Oct 31, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

Reparixin in Prevention of Delayed Graft Function After Kidney Transplantation

NCT00248040
View directory record Official record
Conditions
Ischemia-Reperfusion Injury, Kidney Diseases
Interventions
Reparixin continuous infusion, reparixin intermittent infusion, placebo infusion
Drug · Other
Lead sponsor
Dompé Farmaceutici S.p.A
Industry
Eligibility
18 Years to 65 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Minneapolis, Minnesota • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Oct 31, 2026, 5:05 PM EDT
Completed Phase 1 Interventional

Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer

NCT01493310
View directory record Official record
Conditions
Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
mifepristone, placebo, nab-paclitaxel
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
2
States / cities
Chicago, Illinois • Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Oct 31, 2026, 5:05 PM EDT